Elevance Renewable Sciences, Evonik Announce Metathesis Catalysts License Agreement

Evonik Industries and Elevance Renewable Sciences, Incorporated, Bolingbrook, Ill. have entered into a license agreement regarding Evonik’s U.S. patents Nos. 7,738,528 and 7,652,145, directed to metathesis technology excluding Evonik’s catMETium RF product portfolio. The companies also intend to cooperate in further developing application of metathesis catalysts within Elevance’s business scope.

Elevance has developed technology for manufacturing specialty chemicals from natural oils such as soybean, palm, rapeseed, algae and Jatropha. It manufactures oils, lubricants additives, antimicrobials and other chemicals from such bio-renewables, and competes with petrochemical based products.

“Metathesis reactions are a key step in our bio-refinery process to make the conversion from natural oils to specialty chemicals,” said K’Lynne Johnson, CEO of Elevance. “Evonik’s licensed metathesis catalysts complement our existing catalyst portfolio.”

Evonik has developed metathesis catalysts within its homogeneous catalysts portfolio. “We are looking forward to Elevance’s successful application of innovative metathesis reactions in the conversion of natural oils”, says Dr. Wilfried Eul, senior vice president and head of Evonik’s Catalyst Business.

Company

Logo:

Evonik Nutrition & Care GmbH (Hanau)

Rodenbacher Chaussee 4
63457 Hanau
Germany

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read